Why real-world HCP insight is becoming a commercial advantage

Tern plc

Pharma companies have used healthcare professional personas for years, but many are still built on limited interviews, workshops and internal assumptions. That makes them useful for alignment, but less useful for execution. If personas do not reflect how clinicians actually think, speak and make decisions in practice, they can weaken messaging, waste spend and reduce the impact of evidence.

Traditional approaches tend to capture what healthcare professionals say in a formal research setting. They are less effective at showing what drives behaviour in real clinical environments, where time pressure, patient complexity, reimbursement issues and changing guidance all shape decisions. As a result, a persona can look credible on paper while failing to explain what really affects uptake.

If a company is working from an outdated or simplified view of its audience, it may focus on the wrong barriers, use evidence in the wrong way or miss the language that actually builds confidence.

The value here is not simply richer insight. It is better accuracy. Real-world language can reveal how clinicians frame problems, what concerns they return to, what evidence they trust and what practical issues affect action. That produces a more grounded view of the audience and gives teams a stronger basis for message development.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search